Stay updated on Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial

Sign up to get notified when there's something new on the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The clinical trial record for ibrutinib and nivolumab in previously treated metastatic kidney cancer is now displayed, with study details, participation criteria, treatment and outcome information, and a linked protocol and statistical analysis plan.
    Difference
    49%
    Check dated 2026-11-08T14:44:21.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0, while the study record remains inaccessible behind a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T15:53:35.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A sitewide NIH notice announces that federal agencies are using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) during a transition.
    Difference
    1%
    Check dated 2026-10-25T15:45:47.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T22:20:47.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The site's footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T22:21:29.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error screen (with 403 message and standard header/footer), reflecting an access issue rather than an update to the study information.
    Difference
    19%
    Check dated 2026-09-20T22:37:44.000Z thumbnail image

Stay in the know with updates to Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab in Metastatic Kidney Cancer Clinical Trial page.